Curis (NASDAQ:CRIS) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen lowered shares of Curis (NASDAQ:CRIS – Free Report) from a hold rating to a sell rating in a research note published on Saturday morning,Wall Street Zen reports.

Several other research analysts have also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a report on Thursday, October 15th. Zacks Research raised Curis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 9th. Finally, HC Wainwright restated a “buy” rating on shares of Curis in a report on Monday, August 17th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $43.00.

Read Our Latest Stock Report on Curis

Curis Price Performance

CRIS opened at $0.43 on Friday. The company has a market capitalization of $4.06 million, a price-to-earnings ratio of -0.07 and a beta of 3.28. Curis has a 1-year low of $0.33 and a 1-year high of $28.40. The business has a 50 day moving average price of $0.69 and a two-hundred day moving average price of $7.77.

Curis (NASDAQ:CRIS – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The biotechnology company reported ($1.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.01) by $0.07. Equities analysts expect that Curis will post -8.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Curis

Several large investors have recently made changes to their positions in CRIS. Focused Wealth Management Inc acquired a new stake in shares of Curis in the 2nd quarter valued at $26,000. BlackRock Inc. bought a new position in shares of Curis in the 2nd quarter valued at approximately $28,000. Flputnam Investment Management Co. acquired a new stake in Curis in the 2nd quarter worth approximately $128,000. Renaissance Technologies LLC lifted its holdings in Curis by 52.2% in the 1st quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock worth $201,000 after purchasing an additional 125,823 shares during the last quarter. Finally, Cable Car Capital LP acquired a new stake in Curis in the 2nd quarter worth approximately $696,000. Institutional investors own 29.97% of the company’s stock.

About Curis

(Get Free Report)

Curis, Inc. is a clinical-stage biotechnology company focused on developing treatments for cancer. Its research centers on targeted therapies designed to interfere with biological pathways involved in tumor growth and survival. The company’s clinical pipeline has included emavusertib, an oral small-molecule inhibitor of IRAK4 and FLT3 being investigated for certain blood cancers and other malignancies. Curis has also worked with partners to develop cancer drug candidates. Historically, Curis collaborated with Genentech on the development of Erivedge (vismodegib), a Hedgehog pathway inhibitor approved to treat certain cases of advanced basal cell carcinoma.

Further Reading

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.